Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record.

Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion

Open access
Lipšic, Erik, van der Meer, Peter, Henning, Robert H, Suurmeijer, Albert J. H, Boddeus, Kristien M, van Veldhuisen, Dirk J, van Gilst, Wiek H, Schoemaker, Regien G · 2004 · Journal of Cardiovascular Pharmacology

Abstract

Erythropoietin (EPO) is a hormone known to stimulate hematopoiesis. However, recent research suggests additional properties of EPO, such as protection against ischemia/reperfusion (I/R) injury in various tissues. We studied the effect of timing of EPO administration on cardioprotection during I/R in the heart. Male Sprague-Dawley rats were subjected to 45 minutes of coronary occlusion, followed by 24 hours of reperfusion. Animals were randomized to receive saline or single dose of EPO (5,000 IU/kg) either 2 hours before I/R, at the start of ischemia, or after the onset of reperfusion. The ratio of infarct area/area at risk (planimetry), left ventricular (LV) function (pressure development), and apoptosis (number of active caspase-3 positive cells) were determined after 24-hour reperfusion. Administration of EPO during different time points resulted in a 19 to 23% (P < 0.05) reduction in the infarct area/area at risk, which was accompanied by a trend toward better LV hemodynamic parameters. Apoptosis was significantly attenuated in groups treated with EPO at the start of ischemia (29% reduction) and after the onset of reperfusion (38%), and to a lesser extent (16%) in the group pre-treated with EPO. Thus, in vivo administration of EPO at different time points protects the myocardial structure and preserves cardiac function during I/R. Cardioprotective effect of EPO is associated with inhibition of apoptosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.fjc.0000140209.04675.c3

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Lipšic, E., van der Meer, P., Henning, R. H., Suurmeijer, A. J. H., Boddeus, K. M., van Veldhuisen, D. J., van Gilst, W. H., & Schoemaker, R. G.
Venue
Journal of Cardiovascular Pharmacology
Published
2004-10
Volume
44
Issue
4
Pages
473-479
ISSN
0160-2446 (ISSN-L)
OpenAlex
W2157312122
Cited by
166
References
0
FWCI
11.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion. https://app.cochat.ai/papers/10.1097/01.fjc.0000140209.04675.c3
The paper
Lipšic, E., van der Meer, P., Henning, R. H., Suurmeijer, A. J. H., Boddeus, K. M., van Veldhuisen, D. J., van Gilst, W. H., & Schoemaker, R. G. (2004). Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/01.fjc.0000140209.04675.c3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.